Potential deals for Silence Therapeutics reassure analysts as losses widen
This article was originally published in Scrip
Executive Summary
Silence Therapeutics has reported falling revenues and widening losses in the first half of 2008. However, it says that it remains focused on securing further deals to develop its short interfering RNA (siRNA) drugs, AtuRNAi, reassuring analysts about its future growth.